The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Cyclosporine for Ocular Inflammatory Diseases
Open accessAbstract
Purpose To evaluate the clinical outcomes of cyclosporine treatment for non-infectious ocular inflammation Design Retrospective cohort study Participants Three hundred seventy-three patients with non-infectious ocular inflammation managed at four tertiary ocular inflammation clinics in the United States observed to use cyclosporine as a single non-corticosteroid immunosuppressive agent to their treatment regimen, between 1979-2007 inclusive. Methods Participants were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Demographic and clinical characteristics, including dosage of cyclosporine and main outcome measures were obtained for every eye of every patient at every visit via medical record review by trained expert reviewers. Main Outcome Measures: Control of inflammation, sustained control after reducing corticosteroid dosages, and discontinuation of therapy because of toxicity. Results Of the 373 patients (681 eyes) initiating cyclosporine monotherapy, 33.4% by six months and 51.9% by one year gained sustained, complete control of inflammation over at least two visits spanning at least 28 days. Approximately 25% more improved to a level of slight inflammatory activity by each of these time points. Corticosteroid-sparing success (completely controlled inflammation for at least 28 days with prednisone 10 mg/day or less) was achieved by 22.1% by six months and 36.1% within one year. Toxicity led to discontinuation of therapy within one year by 10.7% of the population. Patients over 55 years of age were over 3-fold more likely to discontinue therapy because of toxicity than patients ages 18-39 years. Doses of 151-250 mg/day tended to be more successful than lower doses, and were not associated with a higher discontinuation for toxicity rate; higher doses did not appear to offer a therapeutic advantage. Conclusion Cyclosporine, with corticosteroid therapy as indicated, was modestly effective for controlling ocular inflammation. Our data support a preference for cyclosporine adult dosing between 151-250 mg/day. While cyclosporine was tolerated by the majority of patients, toxicity was much more frequent with increasing age; alternative agents may be preferred for patients over 55 years of age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
(2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.057 · Cited by 4,396
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Jabs, D. A., Rosenbaum, J. T., Foster, C. S., Holland, G. N., Jaffe, G. J., Louie, J. S., Nussenblatt, R. B., Stiehm, E. R., Tessler, H., Van Gelder, R. N., et al. (2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00659-0 · Cited by 995
Self-citationMasuda, K., Urayama, A., Kogure, M., Nakajima, A., Nakae, K., & Inaba, G. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92381-7 · Cited by 490
Nussenblatt, R. B., Mittal, K. K., Ryan, S., Richard Green, W., & Edward Maumenee, A. (1982) · American Journal of Ophthalmology · doi:10.1016/0002-9394(82)90069-1 · Cited by 351
Self-citationMethotrexate for Ocular Inflammatory Diseases
Gangaputra, S., Newcomb, C. W., Liesegang, T. L., Kaçmaz, R. O., Jabs, D. A., Levy-Clarke, G. A., Nussenblatt, R. B., Rosenbaum, J. T., Suhler, E. B., & Thorne, J. E. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.04.020 · Cited by 330
Self-citationNussenblatt, R. B., Palestine, A. G., & Chan, C.-C. (1983) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)77814-6 · Cited by 323
Self-citationUSES AND ABUSES OF CHLORMETHIAZOLE
Exton-Smith, A. N., Mclean, A. E. M., Majumdar, S., Glatt, M. M., & Scott, C. J. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92998-2 · Cited by 309
Cited by
Understanding uveitis: The impact of research on visual outcomes
de Smet, M. D., Taylor, S. R. J., Bodaghi, B., Miserocchi, E., Murray, P. I., Pleyer, U., Zierhut, M., Barisani-Asenbauer, T., LeHoang, P., & Lightman, S. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.06.005 · Cited by 340
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis
Dick, A. D., Rosenbaum, J. T., Al-Dhibi, H. A., Belfort, R., Brézin, A. P., Chee, S. P., Davis, J. L., Ramanan, A. V., Sonoda, K.-H., Carreño, E., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.11.017 · Cited by 285
Self-citationPasadhika, S., & Rosenbaum, J. T. (2015) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2015.08.009 · Cited by 267
Self-citationCorticosteroid-sparing therapy: practice patterns among uveitis specialists
Esterberg, E., & Acharya, N. R. (2012) · Journal of Ophthalmic Inflammation and Infection · doi:10.1007/s12348-011-0047-5 · Cited by 58
Wilson, L., Lewis, K. E., Evans, L. S., Dillon, S. R., & Pepple, K. L. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.3.27 · Cited by 5
Metadata
- Authors
- Kaçmaz, R. O., Kempen, J. H., Newcomb, C., Daniel, E., Gangaputra, S., Nussenblatt, R. B., Rosenbaum, J. T., Suhler, E. B., Thorne, J. E., Jabs, D. A., Levy-Clarke, G. A., & Foster, C. S.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 117
- Issue
- 3
- Pages
- 576-584
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2035244366
- Cited by
- 265
- References
- 26
- FWCI
- 17.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclosporine for Ocular Inflammatory Diseases. https://app.cochat.ai/papers/10.1016/j.ophtha.2009.08.010
- The paper
- Kaçmaz, R. O., Kempen, J. H., Newcomb, C., Daniel, E., Gangaputra, S., Nussenblatt, R. B., Rosenbaum, J. T., Suhler, E. B., Thorne, J. E., Jabs, D. A., Levy-Clarke, G. A., & Foster, C. S. (2010). Cyclosporine for Ocular Inflammatory Diseases. Ophthalmology. https://doi.org/10.1016/j.ophtha.2009.08.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.